SNHG15 promotes gallbladder cancer progression by enhancing the autophagy of tumor cell under nutrition stress.
Gallbladder cancer
SNHG15
TSC2
autophagy
Journal
Cell cycle (Georgetown, Tex.)
ISSN: 1551-4005
Titre abrégé: Cell Cycle
Pays: United States
ID NLM: 101137841
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
pmc-release:
05
12
2024
medline:
7
12
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
Gallbladder cancer (GBC) is a major malignant carcinoma of the biliary tract with extremely poor prognosis. Currently, there is no useful therapy strategies for GBC treatment, indicating the unmet mechanism researches for GBC. In this study, our data showed that SNHG15 expression significantly up-regulated and its high expression associated with poor overall survival of patients suffer from GBC. Functional experiments showed that SNHG15 depletion delayed the proliferation and enhanced the apoptosis of GBC tumor cells under the nutrition stress condition, which further confirmed in the subcutaneous xenograft model and liver metastasis model. Mechanistically, SNHG15 could interact with AMPK and facilitate the phosphorylation of AMPK to Tuberous sclerosis complex TSC2, resulting in mTOR suppression and autophagy enhancement, and finally, conferring the GBC cell sustain proliferation under nutrition stress. Taken together, our findings revealed that SNHG15 promotes GBC tumor progression by enhancing the autophagy under poor nutrition tumor microenvironment, which could be a promising targets for GBC.
Identifiants
pubmed: 37937948
doi: 10.1080/15384101.2023.2278339
pmc: PMC10732635
doi:
Substances chimiques
AMP-Activated Protein Kinases
EC 2.7.11.31
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2130-2141Références
Signal Transduct Target Ther. 2020 Oct 7;5(1):230
pubmed: 33028805
J Exp Clin Cancer Res. 2019 Aug 28;38(1):380
pubmed: 31462285
Int Heart J. 2022;63(3):578-590
pubmed: 35650158
Cancer Immunol Res. 2021 Dec;9(12):1383-1399
pubmed: 34667108
J Cell Physiol. 2018 Sep;233(9):7164-7172
pubmed: 29630731
EMBO Rep. 2017 Oct;18(10):1837-1853
pubmed: 28887321
Dis Mon. 2021 Jul;67(7):101130
pubmed: 33478678
Cancer Res. 2013 Apr 15;73(8):2628-38
pubmed: 23370326
Cell. 2020 Nov 25;183(5):1151-1161
pubmed: 33068526
Nat Commun. 2019 May 3;10(1):2045
pubmed: 31053733
Cancer Manag Res. 2019 Jul 01;11:5961-5969
pubmed: 31308739
Genes Dev. 2011 May 15;25(10):1041-51
pubmed: 21576264
Cell Metab. 2013 Jan 8;17(1):113-24
pubmed: 23274086
Mol Cell. 2013 Oct 24;52(2):161-72
pubmed: 24095280
Nat Cell Biol. 2022 Oct;24(10):1528-1540
pubmed: 36202974
Genomics Proteomics Bioinformatics. 2017 Jun;15(3):177-186
pubmed: 28529100
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Science. 2010 Sep 3;329(5996):1201-5
pubmed: 20647423
EMBO Rep. 2021 Dec 6;22(12):e52124
pubmed: 34647680
Biochim Biophys Acta Gene Regul Mech. 2020 Jun;1863(6):194417
pubmed: 31493559
Nat Rev Genet. 2020 Feb;21(2):102-117
pubmed: 31729473
Nucleic Acids Res. 2021 Jan 8;49(D1):D1251-D1258
pubmed: 33219685
Cancer Lett. 2021 Jul 1;509:81-88
pubmed: 33848519
Mol Ther Nucleic Acids. 2021 Apr 02;24:728-742
pubmed: 33996255
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Nat Rev Drug Discov. 2017 Mar;16(3):167-179
pubmed: 27444227
EMBO J. 2019 Jun 3;38(11):
pubmed: 31053596
Signal Transduct Target Ther. 2020 Aug 27;5(1):174
pubmed: 32855395
Front Immunol. 2021 Jun 24;12:687962
pubmed: 34248974
Adv Exp Med Biol. 2016;937:3-17
pubmed: 27573892
Int J Oncol. 2018 Jul;53(1):384-394
pubmed: 29750422
Cell Death Dis. 2018 Sep 20;9(10):947
pubmed: 30237435
World J Gastroenterol. 2017 Jun 14;23(22):3978-3998
pubmed: 28652652
Adv Exp Med Biol. 2022;1363:121-145
pubmed: 35220568